Journal Watch · Nature Communications · 2026

Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.

High mutational burden, interferon-gamma signaling, early circulating tumor DNA reduction, low baseline serum thymidine kinase activity, and urea cycle dysregulation in the microbiome emerged as potential predictors of response to immune checkpoint inhibitors with platinum.

Garrido-Castro AC, Graham N, Li KX et al.Nature Communications3 min readPharma relevance 98/100

DOI: 10.1038/s41467-026-73085-1PMID: 42140950Study type: randomised / controlled clinical trial

TL;DR

High mutational burden, interferon-gamma signaling, early circulating tumor DNA reduction, low baseline serum thymidine kinase activity, and urea cycle dysregulation in the microbiome emerged as potential predictors of response to immune checkpoint inhibitors with platinum.

Key findings

  • In PD-L1-positive mTNBC patients (n = 24), median PFS was 8.3 vs 4.7 months; median OS was 17.6 vs 10.7 months.
  • Grade ≥3 adverse events occurred in 56.8% of patients in the combination arm and 65.8% in the carboplatin arm.
  • Carboplatin plus nivolumab did not significantly improve PFS compared to carboplatin in patients overall; however, a trend toward improved outcomes was observed in PD-L1-positive mTNBC patients.
  • High mutational burden, interferon-gamma signaling, early circulating tumor DNA reduction, low baseline serum thymidine kinase activity, and urea cycle dysregulation in the microbiome emerged as potential predictors of response to immune checkpoint inhibitors with platinum.

Numbers at a glance (from the abstract)

n = 62n = 241%56.8%65.8%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Biospecimens were collected for correlative analyses. 75 patients were enrolled and treated between 2/2018-9/2020. Among the mITT population (n = 62), median PFS was 4.2 months with carboplatin plus nivolumab vs 5.5 months with carboplatin. Median OS did not significantly differ between arms (16.8 vs 11.1 months, respectively).

Full abstract (original)

Background: This multi-institutional randomized phase II clinical trial (NCT03414684) investigated the efficacy and safety of carboplatin plus nivolumab compared to carboplatin in metastatic triple-negative breast cancer (mTNBC). The primary endpoint was progression-free survival (PFS) in a modified intention-to-treat (mITT) population of patients with chemotherapy-naïve (i.e., first-line) mTNBC. Secondary endpoints included overall survival (OS), confirmed objective response rate, confirmed clinical benefit rate, time to and duration of confirmed objective response, safety, and tolerability. Clinical outcomes were evaluated in the PD-L1-positive subgroup ( ≥ 1% immune cells; SP142 clone) per central review.

What they did: Biospecimens were collected for correlative analyses. 75 patients were enrolled and treated between 2/2018-9/2020. Among the mITT population (n = 62), median PFS was 4.2 months with carboplatin plus nivolumab vs 5.5 months with carboplatin. Median OS did not significantly differ between arms (16.8 vs 11.1 months, respectively).

Results & conclusions: In PD-L1-positive mTNBC patients (n = 24), median PFS was 8.3 vs 4.7 months; median OS was 17.6 vs 10.7 months. Grade ≥3 adverse events occurred in 56.8% of patients in the combination arm and 65.8% in the carboplatin arm. Carboplatin plus nivolumab did not significantly improve PFS compared to carboplatin in patients overall; however, a trend toward improved outcomes was observed in PD-L1-positive mTNBC patients. High mutational burden, interferon-gamma signaling, early circulating tumor DNA reduction, low baseline serum thymidine kinase activity, and urea cycle dysregulation in the microbiome emerged as potential predictors of response to immune checkpoint inhibitors with platinum.

Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-73085-1 · PubMed 42140950.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology, small-molecule drug discovery, microbiome therapeutics — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology · small-molecule drug discovery · microbiome therapeutics

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Nature Communications study find?

High mutational burden, interferon-gamma signaling, early circulating tumor DNA reduction, low baseline serum thymidine kinase activity, and urea cycle dysregulation in the microbiome emerged as potential predictors of response to immune checkpoint inhibitors with platinum.

What type of study is this?

It is a randomised / controlled clinical trial, published in Nature Communications in 2026. Biospecimens were collected for correlative analyses.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41467-026-73085-1. PubMed ID: 42140950. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Garrido-Castro AC, Graham N, Li KX et al.. Carboplatin with or without nivolumab in metastatic triple-negative breast cancer: a randomized phase II trial.. Nature Communications (2026). DOI: 10.1038/s41467-026-73085-1.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/carboplatin-with-or-without-nivolumab-in-metastatic-triple-negative-brea-730851/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides